Funding Opportunity Number: RFA-DK-27-127
Issuing agency: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Application deadline: September 30, 2026 at 5:00 PM local time of the applicant organization. Grants.gov lists September 30, 2026 as the closing date; NIH grant applications and associated documents are due by 5:00 PM local time of the applicant organization unless the specific opportunity states otherwise.
Funding: Grants.gov reports $3,745,000 in total program funding and approximately 5 expected awards. The current federal synopsis does not publish an award minimum or maximum, so Atlas does not infer a per-applicant ceiling from the program total. Cost sharing or matching is not required.
Purpose: The CCEH program supports a national network of centers providing state-of-the-art resources, services, expertise, enrichment activities, and pilot/feasibility support to strengthen nonmalignant hematology research. Each center is expected to support one to three Biomedical Research Cores plus an Administrative Core with an Enrichment Program and to collaborate with NIDDK, the Hematology Coordinating Center, and the other CCEH centers.
Eligibility: Eligible domestic applicant types include public and private institutions of higher education, nonprofit organizations, small businesses and other for-profit organizations, state and local governments, Tribal governments and organizations, independent school districts, public and Indian housing authorities, and other eligible domestic organizations identified in the NOFO. Non-U.S. organizations are not eligible to apply under the current posted notice. Foreign components and monetary foreign subawards/subcontracts are restricted as described in the NOFO and current NIH policy.
Submission and source controls: The opportunity is posted on Grants.gov as Version 1, posted August 31, 2026, with the current full-announcement document RFA-DK-27-127-Full-Announcement.html. Applicants must use the current Grants.gov application package and controlling full announcement for required forms, attachments, page limits, budget instructions, and any opportunity-specific submission requirements. Clinical trials are not allowed under this U54.
Atlas assessment: Strong fit for established nonmalignant hematology research institutions with genuine core-facility, scientific-resource, enrichment, and collaborative-network capacity. Structural for-profit eligibility alone does not establish a credible direct Dr. Miltie prime path. Recommended posture is Partner-Led / Established Nonmalignant Hematology Research Center unless all scientific, institutional, core-resource, and submission requirements can be independently verified.
Atlas score: 94/100.